Circulating melanoma cells and survival in metastatic melanoma

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 755-760

  Rao, C ^a   Bui, T ^a   Connelly, M ^a   Doyle, G ^b   Karydis, I ^c   Middleton, M R ^c   Clack, G ^d   Malone, M ^d   Coumans, F A W ^d   Terstappen, Leon W M M ^d  

^a Veridex LLC   (United States)

^b University of Oxford ^*

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Circulating tumor cells; Melanoma; Metastasis; Minimal residual disease

Indexed keywords

CD146 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER PATIENT; CELL ISOLATION; CELL SURVIVAL; CIRCULATING MELANOMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STAINING; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL COUNT; CELL PROLIFERATION; FEMALE; HUMANS; MALE; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 79952010767     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.896     Document Type: Article

References (34)

1. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe A, Uhr JW and Terstappen LWMM: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Clin Cancer Res 10: 6897-6904, 2004. (Pubitemid 39383039)
2. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Rueben JM, Doyle G, Allard WJ, Terstappen LWMM and Hayes DF: Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med 351: 781-791, 2004. (Pubitemid 39095313)
3. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Christopher E, Desch, Miller MC, Doyle GV, Tissing H, Terstappen LWMM and Meropol NJ: The relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213-3221, 2008.
4. DeBono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LWWM, Pienta KJ and Raghavan D: Circulating tumor cells (CTC) predict survival benefit from treatment in metastatic castration resistant prostate cancer (CRPC). Clin Cancer Res 14: 6302-6309, 2008.
5. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M and Pantel K: Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin Cancer Res 13: 920-928, 2007. (Pubitemid 46340368)
6. Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJM, Vos AH, Nagtegaal ID, Terstappen LWMM and Punt CJA: Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 21: 1006-1012, 2010.
7. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone A and Isaacs C: Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27: 5153-5159, 2009.
8. Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle G, Terstappen LWMM and Hayes D: Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 12: 6404-6409, 2006.
9. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN and Cristofanilli M: Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27: 3303-3311, 2009.
10. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang HJ, Elashoff RM, Takeuchi H, Umetani N and Hoon DSB: Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial: J Clin Oncol 23: 8057-8064, 2005. (Pubitemid 46657408)
11. Mocellin S, Hoon D, Ambrosi A, Nitti D and Rossi CR: The prognostic value of circulating tumor cells in patients with melanoma: A systematic review and meta-analysis. Clin Cancer Res 12: 4605-4613, 2006. (Pubitemid 44297811)
12. Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanger U, Rassner G, Riethmuller G, Fierlbeck G and Klein CA: Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 10: 531-537, 2004. (Pubitemid 38173991)
13. Ulmer A, Beutel J, Susskind D, Hilgers RD, Ziemssen F, Luke M, Rocken M, Rohrbach M, Fierlbeck G, Bartz-Schmidt KU and Grisanti S: Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res 14: 4469-4474, 2008.
14. Kagan M, Howard D, Bendele T, Mayes J, Silvia J, Repollet M, Doyle J, Allard J, Tu N, Bui T, Russell T, Rao C, Hermann M, Rutner H and Terstappen LWMM: A sample preparation and analysis system for identification of circulating tumor cells. J Clinical Ligand Assay 25: 104-110, 2002. (Pubitemid 34984736)
15. Hsu MY, Meier F and Herlyn M: Melanoma development and progression: a conspiracy between tumor and host. Differentiation 70: 522-536, 2002. (Pubitemid 36194317)
16. Johnson JP: Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 18: 345-357, 1999.
17. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X and Bar-Eli M: Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62: 5106-5114, 2002. (Pubitemid 34984440)
18. Shih IM: The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 189: 4-11, 1999.
19. Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LWMM: Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71: 105-113, 2007. (Pubitemid 46238939)
20. Liberi PA, Rao CG and Terstappen LWMM: Optimization of ferrofluids and protocols for the enrichment of breast tumor cells in blood. J Magnetism Magnetic Materials 225: 301-307, 2001. (Pubitemid 32335309)
21. Bumol TF and Reisfeld RA: Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci USA 79: 1245-1249, 1982. (Pubitemid 12105584)
22. Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ and Reisfeld RA: Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93: 9710-9715, 1996. (Pubitemid 26296674)
23. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA and McCarthy JB: Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 21: 881-891, 2004. (Pubitemid 38821978)
24. Tibbe AGJ, de Grooth BG, Greve J, Dolan GJ, Rao C and Terstappen LWMM: Magnetic field design for selecting and aligning immunomagnetic labeled cells. Cytometry 47: 163-172, 2002. (Pubitemid 34242029)
25. Beaty MW, Fetsch P, Wilder AM, Marincola F and Abati A: Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody. Cancer 81: 57-63, 1997.
26. Hoashi T, Watabe H, Muller J, Yamaguchi Y, Vieira WD and Hearing VJ: MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem 280: 14006-14016, 2005. (Pubitemid 40517302)
27. Zubovits J, Buzney E, Yu L and Duncan LM: HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol 35: 217-23, 2004. (Pubitemid 38240905)
28. Galanzha EI, Shashkov EV, Spring PM, Suen JY and Zharov VP: In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res 69: 7926-7934, 2009.
29. Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O'Hara SM, Russell T and Terstappen LWMM: Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry 62A: 46-53, 2004. (Pubitemid 39473452)
30. Smeradge J, Doyle GV, Repollet M, Terstappen LWMM, Hayes D: Apoptosis and Bcl-2 expression of circulating tumor cells in metastatic breast cancer. Proc Annu Meet Am Assoc Cancer Res 47: A792, 2006.
31. Moretti S, Massbrio R, Brogelli L, Novelli M, Giannotti B and Bernengo MG: Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. J Invest Dermatol 95: 320-324, 1990. (Pubitemid 20261866)
32. Ben-Izhak O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J, Cagnano M, Cohen H and Sabo E: Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 41: 519-525, 2002. (Pubitemid 36693597)
33. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P and Guerry DP: Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23: 8048-8056, 2005. (Pubitemid 46657407)
34. Pearl RA, Pacifico MD, Richman PI, Stott DJ, Wilson GD and Grobbelaar AO: Ki-67 expression in melanoma. A potential method of risk assessment for the patient with a positive sentinel node: J Exp Clin Cancer Res 26: 109-115, 2007. (Pubitemid 46650051)